ZA202406375B - Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof - Google Patents
Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereofInfo
- Publication number
- ZA202406375B ZA202406375B ZA2024/06375A ZA202406375A ZA202406375B ZA 202406375 B ZA202406375 B ZA 202406375B ZA 2024/06375 A ZA2024/06375 A ZA 2024/06375A ZA 202406375 A ZA202406375 A ZA 202406375A ZA 202406375 B ZA202406375 B ZA 202406375B
- Authority
- ZA
- South Africa
- Prior art keywords
- quinolines
- pyrazolo
- substituted
- preparation
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256260P | 2021-10-15 | 2021-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202406375B true ZA202406375B (en) | 2025-01-29 |
Family
ID=85988576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/06375A ZA202406375B (en) | 2021-10-15 | 2024-08-20 | Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250011319A1 (enExample) |
| EP (1) | EP4416146A4 (enExample) |
| JP (1) | JP7900840B2 (enExample) |
| KR (1) | KR20240093606A (enExample) |
| CN (1) | CN118076605A (enExample) |
| AU (1) | AU2022364646B2 (enExample) |
| CA (1) | CA3233233A1 (enExample) |
| MX (1) | MX2024004569A (enExample) |
| TW (2) | TWI863003B (enExample) |
| WO (1) | WO2023064133A1 (enExample) |
| ZA (1) | ZA202406375B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118666857B (zh) * | 2024-06-26 | 2025-02-25 | 江西农业大学 | 一种喹啉类化合物及其在农用杀菌剂中的应用 |
| WO2026080918A1 (en) * | 2024-10-11 | 2026-04-16 | Lomond Therapeutics, Inc. | Synthesis of a tetrahydroisoquinolin-pyrazoloquinolin compound and pharmaceutically acceptable salts thereof |
| WO2026080917A1 (en) * | 2024-10-11 | 2026-04-16 | Lomond Therapeutics, Inc. | Polymorphs and solid forms of a tetrahydroisoquinolinpyrazoloquinolin compound, and pharmaceutical compositions thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| RS61919B1 (sr) * | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibitori hpk1 i postupci za njihovo korišćenje |
| MA55478A (fr) * | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques de hpk1 |
| WO2021142252A1 (en) | 2020-01-10 | 2021-07-15 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CN121270550A (zh) * | 2020-04-16 | 2026-01-06 | 因赛特公司 | 稠合三环kras抑制剂 |
-
2022
- 2022-10-03 US US18/701,223 patent/US20250011319A1/en active Pending
- 2022-10-03 AU AU2022364646A patent/AU2022364646B2/en active Active
- 2022-10-03 KR KR1020247016127A patent/KR20240093606A/ko active Pending
- 2022-10-03 CA CA3233233A patent/CA3233233A1/en active Pending
- 2022-10-03 JP JP2024522243A patent/JP7900840B2/ja active Active
- 2022-10-03 CN CN202280067758.XA patent/CN118076605A/zh active Pending
- 2022-10-03 MX MX2024004569A patent/MX2024004569A/es unknown
- 2022-10-03 WO PCT/US2022/045555 patent/WO2023064133A1/en not_active Ceased
- 2022-10-03 EP EP22881570.0A patent/EP4416146A4/en active Pending
- 2022-10-14 TW TW111139090A patent/TWI863003B/zh active
- 2022-10-14 TW TW113124708A patent/TW202442645A/zh unknown
-
2024
- 2024-08-20 ZA ZA2024/06375A patent/ZA202406375B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250011319A1 (en) | 2025-01-09 |
| EP4416146A1 (en) | 2024-08-21 |
| CN118076605A (zh) | 2024-05-24 |
| MX2024004569A (es) | 2024-04-30 |
| JP2024539633A (ja) | 2024-10-29 |
| AU2022364646B2 (en) | 2025-10-09 |
| TWI863003B (zh) | 2024-11-21 |
| EP4416146A4 (en) | 2025-11-05 |
| WO2023064133A1 (en) | 2023-04-20 |
| KR20240093606A (ko) | 2024-06-24 |
| AU2022364646A1 (en) | 2024-03-28 |
| JP7900840B2 (ja) | 2026-08-05 |
| TW202442645A (zh) | 2024-11-01 |
| TW202317567A (zh) | 2023-05-01 |
| CA3233233A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004569A (es) | 1h-pirazolo[4,3-c]quinolinas sustituidas y metodos de preparacion y uso de estas. | |
| WO2022216971A9 (en) | Pyridazine compounds for inhibiting nlrp3 | |
| MX2023009086A (es) | Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos. | |
| PH12022500017A1 (en) | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | |
| ATE331514T1 (de) | Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase | |
| HRP20050967B8 (hr) | Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze | |
| DE60216281D1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
| MX2024013762A (es) | Inhibidores de fosfatidilinositol 3-cinasa alfa (pi3kalfa) y metodos de uso de los mismos | |
| DE60212627D1 (de) | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen | |
| WO2003024386A3 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis | |
| IL175875A0 (en) | Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon | |
| WO2003002107A3 (en) | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| WO2003072090A3 (en) | Use of tyrosine kinase inhibitors for treating cns disorders | |
| ATE343415T1 (de) | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen | |
| ATE401078T1 (de) | Die verwendung von c-kithemmern zur förderung des haarwuchses | |
| HK20075235A1 (en) | Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof | |
| HK20113541A1 (zh) | 经取代的1h-吡唑并[4，3-c]喹啉、其制备方法及用途 | |
| PH12022550627A1 (en) | ESTROGEN-RELATED RECEPTOR ALPHA (ERRa) MODULATORS | |
| DE60323613D1 (de) | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch | |
| JOP20250005A1 (ar) | مثبطات التيروسين كيناز 2 واستخداماتها | |
| MX2024014447A (es) | Compuestos | |
| MX2024008270A (es) | Inhibidores del linfoma 2 de celulas b. | |
| HK20067397A1 (en) | Compounds having 1h-pyrazolo[4,3-c]pyridin-6-amino as therapeutic agents | |
| HK20079029A1 (zh) | Bcl-2抑制剂 |